- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Patent holdings for IPC class A61P 1/16
Total number of patents in this class: 8178
10-year publication summary
|
212
|
414
|
523
|
587
|
686
|
758
|
729
|
634
|
694
|
70
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Genfit | 283 |
64 |
| Novartis AG | 10494 |
60 |
| Daiichi Sankyo Company, Limited | 1877 |
54 |
| Gilead Sciences, Inc. | 2134 |
53 |
| Albireo AB | 175 |
51 |
| The Regents of the University of California | 20355 |
50 |
| Osaka University | 3360 |
49 |
| Sunshine Lake Pharma Co., Ltd. | 612 |
48 |
| Eli Lilly and Company | 3965 |
46 |
| Takeda Pharmaceutical Company Limited | 2710 |
42 |
| Bristol-myers Squibb Company | 4795 |
38 |
| Pfizer Inc. | 3384 |
38 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 853 |
34 |
| InterCept Pharmaceuticals, Inc. | 203 |
33 |
| Viking Therapeutics, Inc. | 57 |
33 |
| Boehringer Ingelheim International GmbH | 4595 |
32 |
| Chugai Seiyaku Kabushiki Kaisha | 1387 |
32 |
| AstraZeneca AB | 2833 |
30 |
| Kowa Company, Ltd. | 1220 |
29 |
| Regeneron Pharmaceuticals, Inc. | 4505 |
29 |
| Other owners | 7333 |